Managing Type 1 Diabetes During Pregnancy

The Challenge of Balancing Maternal and Fetal Needs

Doctors face significant challenges in managing Type 1 diabetes during pregnancy, as they must consider the health of both the mother and the fetus. Recent research offers potential insights into the most effective insulin prescriptions for pregnant women with diabetes.

Understanding Diabetes in Pregnancy

Diabetes in pregnancy is characterized by elevated blood sugar levels in a mother after the second trimester. There are two main types of diabetes affecting pregnant women: Type 1 diabetes, which is present from birth, and Type 2 or gestational diabetes, which arises during pregnancy. These conditions result from abnormal increases in glucose levels in maternal blood and require management through glucose-lowering medications, such as insulin.

Foetal Development Stages

The developing child in the womb is referred to as a fetus. During pregnancy, the fetus undergoes two primary growth phases. The first phase, occurring in the first trimester, focuses on limb development. The second phase involves the growth of newly formed organs and lasts through the second and third trimesters, culminating in preparation for delivery. Type 1 diabetes significantly impacts this second growth phase, where excess sugar can cause abnormal fetal growth. This enlargement can stretch the mother’s womb and exert pressure on her organs, leading to potential risks during delivery.

The Role of Insulin in Managing Blood Sugar Levels

To mitigate these risks, insulin is administered during pregnancy to regulate excess blood glucose. Various insulin formulations are available, with the most commonly used short-acting types being NPH (Neutral Protamine Hagedorn), glargine, and Continuous Subcutaneous Insulin Infusion (CSII). While insulin lowers blood glucose levels, excessive doses can lead to hypoglycemia, resulting in complications such as stunted growth.

Research on Insulin Effects on Fetal Health

Research led by Chico and colleagues aimed to evaluate the effects of different insulin formulations on fetal health and to identify the safest options for pregnant women. Their findings were published in the European Journal of Obstetrics and Gynaecology and included a cohort of 1,534 participants undergoing treatment for Type 1 diabetes. Among the participants, 55.6% used NPH, 23.2% used glargine, and 21.1% used CSII.

Key Findings from the Study

The study revealed that the use of glargine was linked to a slightly higher incidence of minor malformations in the fetus compared to other insulin formulations. Additionally, CSII was associated with increased risks of miscarriages, preterm births, and abnormally low glucose levels in the fetus. Furthermore, CSII was linked to less stable diabetes control in pregnant women. Notably, the researchers identified a connection between basal insulin use and the likelihood of giving birth to smaller infants, a finding that adds valuable context to existing literature.

Conclusion and Implications for Treatment

In summary, the study concluded that glargine is preferable to other insulin types, including NPH, due to its convenience and better pregnancy outcomes. While CSII therapy presents some adverse outcomes, the debate continues regarding its necessity for women who relied on it prior to pregnancy. These insights will assist obstetricians in determining appropriate treatment strategies for women with Type 1 diabetes prior to conception and in providing necessary support to young women with this condition who have not yet given birth.

Written by Dr. Apollina Sharma, MBBS, GradDip EXMD.